Back to Search
KARA FLAHERTY, M.D.
M.D.
Specialist
NPI: 1225015480IndividualAccepts Medicare
Education
ALBANY MEDICAL COLLEGE OF UNION UNIVERSITY
Class of 1999
Research & Publications (20)
Drug targeting of oncogenic pathways in melanoma.
PMID 19464605·Hematol Oncol Clin North Am·2009
6-review
Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
PMID 19156138·Br J Cancer·2009
6-review
Preclinical and clinical development of targeted therapy in melanoma: attention to schedule.
PMID 19619259·Pigment Cell Melanoma Res·2009
8-other
Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.
PMID 19351826·Cancer Res·2009
6-review
Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers.
PMID 19549767·Clin Cancer Res·2009
8-other
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008.
PMID 19659612·Pigment Cell Melanoma Res·2009
8-other
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.
PMID 19179488·Am J Respir Crit Care Med·2009
8-other
Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
PMID 19401062·J Natl Compr Canc Netw·2009
6-review
Interleukin-17-mediated immunopathogenesis in experimental hypersensitivity pneumonitis.
PMID 19151189·Am J Respir Crit Care Med·2009
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 55 MAIN ST, SUITE 3
ESSEX JUNCTION, VT 05452 - Phone
- (802) 879-1802
Quick Facts
- NPI
- 1225015480
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 27
- Publications
- 20
Are you this provider?
Claim Your Profile